Recent development of drug delivery systems for the treatment of asthma and related disorders

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 3, 2009, Pages 232-239

  Takizawa, Hajime ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asthma; Drug delivery; Dry powder inhalers; Pressurized metered dose inhalers

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHITOSAN; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FORMOTEROL; HEPARIN; HYALURONIC ACID; LIPID; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; NANOPARTICLE; PLACEBO; SALMETEROL; STARCH MICROSPHERE; THEOPHYLLINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; ASTHMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; ENCAPSULATION; HUMAN; INHALATION SPACER; LUNG DISEASE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; PARTICLE SIZE; PARTICULATE MATTER; PATENT; POWDER INHALER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEVERE PERSISTENT ASTHMA; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; SYSTEMIC DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; AEROSOL PROPELLANTS; ASTHMA; DRUG DELIVERY SYSTEMS; EOSINOPHILS; HUMANS; METERED DOSE INHALERS; PARTICLE SIZE; PATENTS AS TOPIC; TH2 CELLS;

EID: 70350778491     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309789257414     Document Type: Article

References (74)

1. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478.
2. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344: 350-362.
3. Barnes PJ. Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 1996; 97(1 Pt 2): 159-168.
4. Takizawa H. Bronchial epithelial cells in allergic reactions. Curr Drug Targets Inflamm Allergy 2005; 4(3): 305-311.
5. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148(4 Pt 2): S1-26.
6. Muir JF. An overview of the clinical efficacy of HFA-BDP in asthma. Respir Med 2000; 94(Suppl D): S17-S20.
7. Donnell D. Optimizing drug delivery to the lung: Design of a CFCfree corticosteroid metered-dose aerosol system. Drug Dev Ind Pharm 2001; 27(2): 111-118.
8. Chougule MB, Padhi BK, Jinturkar KA, Misra A. Development of dry powder inhalers. Recent Pat Drug Deliv Formul 2007; 1(1): 11-21.
9. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med 2008; 102(1): 10-19.
10. Lavorini F, Corbetta L. Achieving asthma control: The key role of inhalers. Breathe 2008; 5: 121-31.
11. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127(1): 335-371.
12. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLI/WHO workshop report. National Institute of Health, National Heart, Lung and Blood Institute, NIH Publication Number 02-3659. Updated November 2006.
13. Crompton G, Duncan J. Clinical assessment of a new breath activated inhaler. Practitioner 1989; 233: 268-269.
14. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002; 109(2 Suppl): S447-460.
15. Kraft M, Pak J, Martin R J, et al. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 2001; 163(7): 1551-1556.
16. Corren J. Small airways disease in asthma. Curr Allergy Asthma Rep 2008; 8(6): 533-539.
17. Deeks ED, Perry CM. Ciclesonide: A review of its use in the management of asthma. Drugs 2008; 68(12): 1741-1770.
18. Kelly HW. Comparison of inhaled corticosteroids: An update. Ann Pharmacother 2009; 43(3): 519-527.
19. Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008; 53(6): 699-723.
20. Melani AS. Inhalatory therapy training: A priority challenge for the physician. Acta Biomed 2007; 78(3): 233-245.
21. Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin Drug Deliv 2007; 4(3): 215-234.
22. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20(3): 290-303.
23. Crosland BM, Johnson MR. Characterization of the spray velocities from a pressurized metered-dose inhaler. J Aerosol Med Pulm Drug Deliv 2009; 22(2): 85-97.
24. Lipworth BJ. The comparative safety/efficacy ratio of HFA-BDP. Respir Med 2000; 94 (Suppl D): S21-S26.
25. Nair A, Clearie K, Daniel M, et al. A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Pulm Pharmacol Ther 2009; 22(4): 305-310.
26. Lyseng-Williamson KA, Simpson D. Budesonide/Formoterol pressurized metered-dose inhaler. Drugs 2008; 68(13): 1855-1864.
27. Miller CJ, Senn S, Mezzanotte WS. Bronchodilation of formoterol administered with budesonide: Device and formulation effects. Contemp Clin Trials 2008; 29(2): 114-124.
28. Chambers F, Ludzik A. in vitro Drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler. J Aerosol Med Pulm Drug Deliv 2009; 22(2): 113-120.
29. Fabbri LM, Nicolini G, Olivieri D, Papi A. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother 2008; 9(3): 479-490.
30. Melani AS. Inhalatory therapy training: A priority challenge for the physician. Acta Biomed 2007; 78(3): 233-245.
31. Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert Opin Drug Deliv 2009; 6(1): 91-102.
32. Engelstättera R, Szlávikb M, Gerbera C, Beck E. Once-daily ciclesonide via metered-dose inhaler: Similar efficacy and safety with or without a spacer. Respir Med 2009 [Epub ahead of print].
33. Chrystyn H. The Diskus: A review of its position among dry powder inhaler devices. Int J Clin Pract 2007; 61(6): 1022-1036.
34. Munzel U, Marschall K, Fyrnys B, Wedel M. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers. Curr Med Res Opin 2005; 21: 827-833.
35. Everard M, Devadason S, Souef P. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997; 91: 624-628.
36. Möller M, Fritsche D, Rivera D, Libertus H. Improvement of asthma therapy by a novel budesonide multidose dry powder inhaler. Drug Res 2003; 53: 562-567.
37. Burnell P, Small T, Doig S, et al. ex-vivo Product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med 2001; 95: 324-330.
38. Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv 2009; 6(1): 38-49.
39. Richter K. Successful use of DPI systems in asthmatic patients-key parameters. Respir Med 2004; 98(Suppl B): S22-27.
40. Vogelberg C, Kremer HJ, Ellers-Lenz B, et al. Clinical evaluation of the peak inspiratory flow generated by children through the Novolizer. Respir Med 2004; 98: 924-931.
41. Prime D, Atkins PJ, Slater A, Sumby B. Review of dry powder inhalers. Adv Drug Del Rev 1997; 26: 51-58.
42. Voss AP, WH. Finlay 2003 Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm 2003; 248: 39-50.
43. Mohammed A, Mazumder MK, Ted B. Martonen. Measurements of electrodynamic effects on the deposition of MDI and DPI aerosols in a replica cast of human oral-pharyngeal-laryngeal airways. J Aerosol Med Pulm Drug Deliv 2008; 22(1): 35-44.
44. Coates MS, Fletcher DF, Chan HK, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci 2004; 11(93): 2863-2876.
45. Vemuri, N., Authelin, J.R., Hosek, P.: WO0032165 (2000).
46. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study. Lancet 2000; 356: 556-561.
47. Woolfe, A.J., Zheng, X.M., Langford, A.: WO0113885 (2001).
48. Kussendrager, K.D., Ellison, M.J.H.: WO020207705 (2002).
49. Staniforth, J.N.: WO9511666 (1995).
50. Hodson, P. D., Smith, D. K., Velasquez, D.J., Wass, A. C.L., Calhoun, C. D.: US5740793 (1998).
51. Radhakrishnan, R., Mihalko, P.J., Abra, R.M.: US5192528 (1993).
52. Hajosa F, Starkb B, Henslera S, Prasslb R, Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm 2008; 357(1-2): 286-294.
53. Kraft KS, Grant M. Preparation of macromolecule-containing dry powders for pulmonary delivery. Methods Mol Biol 2009; 480: 165-174.
54. Misra A, Jinturkar K, Patel D, Lalani J, Chougule M. Recent advances in liposomal dry powder formulations: Preparation and evaluation. Expert Opin Drug Deliv 2009; 6(1): 71-89.
55. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm 2009; [Epub ahead of print].
56. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005; 102: 73-81.
57. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Del Rev 1997; 28: 5-24.
58. Sakon, K., Sakagami, M., Makino, Y., Suzuki, Y., Kobayashi, H.: US05972388 (1997).
59. Hodges, C.C., Lloyd, P.M., Mufson, D., Rogers, D.D., Wensley, M.J.: US200406682716 (2004).
60. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, Ortega HG. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: Implications for establishing bioequivalence of inhaled products. Clin Ther 2009; 31(2): 370-385.
61. Schuster, J.A., Holst, P., Ament, B., Bogdon, K.: US20070256688 (2007).
62. Watanabe, W., Kauppinen, E., Ahonen, P., Brown, D., Muttonen, E.: US20040052732(2004).
63. Melker, R., Van Oostrom, J.H.: US20030159693 (2003).
64. Kleinstreuer, C., Seelecke, S.: US20070044793(2007).
65. White, J., Perfetti, T.A.: US20080110454 (2008).
66. Richardson, T., Venkataraman, G., Qi, Y., Picard, M.: US20050207988 (2005).
67. Momeni A, Mohammadi MH. Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma. J Microencapsul 2009; 9: 1-10.
68. Zapol, W.M.: US5823180 (1998).
69. Chen, J., Eisen, H.N., Ge, Q.: US20060058255 (2006).
70. Guimond A, Viau E, Aubé P, Renzi PM, Paquet L, Ferrari N. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 2008; 21(6): 845-854.
71. Shrewsbury SB, Bosco AP, Uster PS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm 2009; 365(1-2): 12-17.
72. Son YJ, McConville JT. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm 2008; 34(9): 948-959.
73. Dames P, Gleich B, Flemmer A, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007; 2(8): 495-499.
74. Plank C. Nanomagnetosols: Magnetism opens up new perspectives for targeted aerosol delivery to the lung. Trends Biotechnol 2008; 26(2): 59-63.